(VIANEWS) – AbbVie (ABBV), Luxfer Holdings PLC (LXFR), Tekla Healthcare Investors (HQH) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio so far. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. AbbVie (ABBV)
178.27% Payout Ratio
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Earnings Per Share
As for profitability, AbbVie has a trailing twelve months EPS of $2.71.
PE Ratio
AbbVie has a trailing twelve months price to earnings ratio of 59.88. Meaning, the purchaser of the share is investing $59.88 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 56.24%.
Sales Growth
AbbVie’s sales growth is 1.1% for the current quarter and 3.4% for the next.
Yearly Top and Bottom Value
AbbVie’s stock is valued at $162.28 at 20:23 EST, way below its 52-week high of $182.89 and way higher than its 52-week low of $135.85.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jul 15, 2024, the estimated forward annual dividend rate is 6.2 and the estimated forward annual dividend yield is 3.6%.
Volume
Today’s last reported volume for AbbVie is 5514860 which is 1.92% below its average volume of 5623340.
Previous days news about AbbVie (ABBV)
- AbbVie (abbv) stock before Q2 earnings: to buy or not to buy?. According to Zacks on Monday, 22 July, "Michael has been part of AbbVie since its formation and played a key role in establishing its financial planning organization, diversifying its business strategy, navigating the company through Humira’s loss of exclusivity, and supporting important M&A activity. ", "While the CRL highlighted some observations on inspection of one of AbbVie’s third-party manufacturing facilities, it does not involve ABBV-951 or any other AbbVie drug. "
- According to Zacks on Monday, 22 July, "Wednesday will be Chipotle (CME Quick QuoteCME – Free Report) and Thursday AbbVie (ABBV Quick QuoteABBV – Free Report) . "
- According to Zacks on Monday, 22 July, "Wednesday will be Chipotle (CMG Quick QuoteCMG – Free Report) and Thursday AbbVie (ABBV Quick QuoteABBV – Free Report) . "
2. Luxfer Holdings PLC (LXFR)
140.54% Payout Ratio
Luxfer Holdings PLC, a materials technology company, designs, manufactures, and supplies high-performance materials, components, and high-pressure gas cylinders for transportation, defense and emergency response, healthcare, and general industrial end-market applications. It operates in two segments, Gas Cylinders and Elektron. The Gas Cylinders segment manufactures and markets aluminum, titanium, and carbon composite cylinders, which are used for self-contained breathing apparatus that are used by firefighters and other emergency-responders, as well as scuba divers and personnel in potentially hazardous environments, such as mines; and aluminum and composite cylinders for use in the containment of oxygen and other medical gases that are used by patients, healthcare facilities, and laboratories. This segment also offers carbon composite cylinders for compressed natural gas and hydrogen containment in alternative fuel vehicles; lightweight aluminum cylinders for a variety of industrial applications, such as fire extinguishers and containment of high-purity specialty gases; and lightweight aluminum and titanium panels primarily for use in the aerospace and luxury-auto industries. The Elektron segment focuses on specialty materials based on magnesium, zircon sand, and rare earths. It develops and manufactures magnesium alloys; magnesium powders; and magnesium, copper, and zinc photoengraving plates for graphic arts and luxury packaging. This segment also develops and manufactures zirconium-based materials and oxides used as catalysts and in the manufacture of advanced ceramics, fiber-optic fuel cells, and other performance products. Luxfer Holdings PLC has operations in the United States, the United Kingdom, Germany, Italy, France, rest of Europe, the Asia Pacific, Canada, South America, Latin America, and Africa. The company was founded in 1898 and is headquartered in Manchester, the United Kingdom.
Earnings Per Share
As for profitability, Luxfer Holdings PLC has a trailing twelve months EPS of $-0.02.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.14%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 11.1% and positive 425% for the next.
Revenue Growth
Year-on-year quarterly revenue growth declined by 11.7%, now sitting on 393.1M for the twelve trailing months.
Yearly Top and Bottom Value
Luxfer Holdings PLC’s stock is valued at $12.01 at 20:23 EST, way below its 52-week high of $14.24 and way above its 52-week low of $7.55.
Volume
Today’s last reported volume for Luxfer Holdings PLC is 108683 which is 11.47% below its average volume of 122774.
3. Tekla Healthcare Investors (HQH)
126.72% Payout Ratio
Tekla Healthcare Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. It was previously known as H&Q Healthcare Investors. Tekla Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.
Earnings Per Share
As for profitability, Tekla Healthcare Investors has a trailing twelve months EPS of $1.31.
PE Ratio
Tekla Healthcare Investors has a trailing twelve months price to earnings ratio of 14.18. Meaning, the purchaser of the share is investing $14.18 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.33%.
Volume
Today’s last reported volume for Tekla Healthcare Investors is 1077560 which is 544.34% above its average volume of 167232.
Revenue Growth
Year-on-year quarterly revenue growth declined by 5.7%, now sitting on 9.97M for the twelve trailing months.
Yearly Top and Bottom Value
Tekla Healthcare Investors’s stock is valued at $18.57 at 20:23 EST, below its 52-week high of $18.97 and way higher than its 52-week low of $14.31.
Moving Average
Tekla Healthcare Investors’s value is above its 50-day moving average of $17.32 and way higher than its 200-day moving average of $16.54.
4. TeklaLife Sciences Investors (HQL)
99.25% Payout Ratio
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Earnings Per Share
As for profitability, TeklaLife Sciences Investors has a trailing twelve months EPS of $1.34.
PE Ratio
TeklaLife Sciences Investors has a trailing twelve months price to earnings ratio of 11.42. Meaning, the purchaser of the share is investing $11.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.28%.
Moving Average
TeklaLife Sciences Investors’s worth is above its 50-day moving average of $14.07 and way higher than its 200-day moving average of $13.38.
5. Hercules Technology Growth Capital (HTGC)
86.82% Payout Ratio
Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, development and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest; particularly in the areas of software, biotech and information services. The firm prefers to invest between $10 million to $250 million in equity per transactions. It invests generally between $1 million to $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in December 2003 and is based in Palo Alto, California with additional offices in Connecticut; Boston, Massachusetts; San Diego, California; Westport, Connecticut; Elmhurst, Illinois; Santa Monica, California; McLean, Virginia; New York, New York; Radnor, Pennsylvania; and Washington, District of Columbia and London, United Kingdom.
Earnings Per Share
As for profitability, Hercules Technology Growth Capital has a trailing twelve months EPS of $2.2.
PE Ratio
Hercules Technology Growth Capital has a trailing twelve months price to earnings ratio of 9.63. Meaning, the purchaser of the share is investing $9.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.73%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 3.8% and a negative 1.9%, respectively.
Yearly Top and Bottom Value
Hercules Technology Growth Capital’s stock is valued at $21.18 at 20:23 EST, below its 52-week high of $21.61 and way higher than its 52-week low of $15.02.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of $1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
